<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Della Bella, Elena</dc:creator>
  <dc:creator>Buetti-Dinh, Antoine</dc:creator>
  <dc:creator>Licandro, Ginevra</dc:creator>
  <dc:creator>Ahmad, Paras</dc:creator>
  <dc:creator>Basoli, Valentina</dc:creator>
  <dc:creator>Alini, Mauro</dc:creator>
  <dc:creator>Stoddart, Martin J.</dc:creator>
  <dc:date>2021-04-30</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Despite the huge body of research on osteogenic differentiation and bone tissue engineering, the translation  potential of in vitro results still does not match the effort employed. One reason might be that the protocols used  for in vitro research have inherent pitfalls. The synthetic glucocorticoid dexamethasone is commonly used in  protocols for trilineage differentiation of human bone marrow mesenchymal stromal cells (hBMSCs). However, in  the case of osteogenic commitment, dexamethasone has the main pitfall of inhibiting terminal osteoblast  differentiation, and its pro-adipogenic effect is well known. In this work, we aimed to clarify the role of  dexamethasone in the osteogenesis of hBMSCs, with a particular focus on off-target differentiation. The results  showed that dexamethasone does induce osteogenic differentiation by inhibiting SOX9 expression, but not directly  through RUNX2 upregulation as it is commonly thought. Rather, PPARG is concomitantly and strongly  upregulated, leading to the formation of adipocyte-like cells within osteogenic cultures. Limiting the exposure to  dexamethasone to the first week of differentiation did not affect the mineralization potential. Gene expression  levels of RUNX2, SOX9, and PPARG were simulated using approximate Bayesian computation based on a  simplified theoretical model, which was able to reproduce the observed experimental trends but with a different  range of responses, indicating that other factors should be integrated to fully understand how dexamethasone  influences cell fate. In summary, this work provides evidence that current in vitro differentiation protocols based on  dexamethasone do not represent a good model, and further research is warranted in this field.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://susi.usi.ch/global/documents/319367</dc:identifier>
  <dc:identifier>https://localhost:5000/ark:/12658/srd1319367</dc:identifier>
  <dc:identifier>https://susi.usi.ch/documents/319367/files/Licandro_ijms_2021.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms22094785</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/ark/12658/srd1319367</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>CC BY</dc:rights>
  <dc:source>International journal of molecular sciences. - MDPI. - 2021, vol. 22, no. 9, p. 16</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Osteogenesis</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Glucocorticoids</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Transcription factors</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">MSC</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Gene expression</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Approximate Bayesian computation (ABC)</dc:subject>
  <dc:subject>info:eu-repo/classification/udc/61</dc:subject>
  <dc:title xmlns:ns7="xml" ns7:lang="en">Dexamethasone induces changes in osteogenic differentiation of human mesenchymal stromal cells via SOX9 and PPARG, but not RUNX2</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
